Product Description
Mechanisms of Action: Potassium Channel Opener
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Denmark | Dominican Republic | Egypt | France | Germany | India | Ireland | Italy | Japan | Korea | Lebanon | Malta | Netherlands | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Slovenia | Sri Lanka | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Angina Pectoris
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20231963 | P1 |
Completed |
Angina Pectoris |
2023-06-01 |
|
CTR20230455 | P1 |
Not yet recruiting |
Angina Pectoris |
None |